<DOC>
	<DOCNO>NCT01468285</DOCNO>
	<brief_summary>Betahistine may provide benefit enhancement Cerebral Blood Flow ( CBF ) . This placebo-controlled pharmacodynamic treatment study primarily explore effect betahistine cerebral blood flow measure dynamic contrast-enhanced MRI imaging , patient population MRI evidence cerebrovascular compromise . Also measure CBF change correlate gait cognitive change .</brief_summary>
	<brief_title>The CBF Study Evaluating Effect Betahistine Cerebral Blood Flow</brief_title>
	<detailed_description />
	<mesh_term>Betahistine</mesh_term>
	<criteria>1 . Subjects gait balance disorder problem 2 . Male female subject age 40 year . 3 . Absence known contraindication betahistine treatment . 4 . Currently betahistine ( formulation ) treatment least 45 day prior inclusion study . 5 . Subject consuming caffeinated alcoholic beverage stable consumption throughout study period . 1 . History discontinuation betahistine treatment ( formulation ) past due lack efficacy side effect . 2 . Subjects treat antihistamine monoamine oxidase ( MAO ) inhibitor 30 day prior inclusion study . 3 . Subjects hypersensitivity active substance excipients drug . 4 . Phaeochromocytoma 5 . Porphyria</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>interventional , placebo control</keyword>
</DOC>